Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CVS Health (CVS)

CVS Health replaces CEO Karen Lynch with David Joyner; Q3 adjusted EPS $1.05 to $1.10

Negative Impact 4 of 5 leadership Written later

CVS Health appointed David Joyner as President and Chief Executive Officer effective October 17, 2024, replacing Karen Lynch, who also left the Board, and named Roger Farah Executive Chairman. The company also gave preliminary third quarter 2024 guidance of $0.03 to $0.08 GAAP diluted EPS and $1.05 to $1.10 Adjusted EPS, citing about $1.1 billion in premium deficiency reserve charges and about $1.2 billion in restructuring charges, and told investors not to rely on its prior guidance from August 7, 2024.

Key points

  • David Joyner, previously executive vice president and president of Pharmacy Services, became CEO effective October 17, 2024; Roger Farah is Executive Chairman.
  • Preliminary Q3 2024 GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10.
  • Premium deficiency reserve charges of about $1.1 billion lowered Q3 Adjusted EPS by $0.63; medical benefit ratio expected at about 95.2%.
  • Karen Lynch will provide advisory services for six months at a $375,000 monthly fee; her non-compete extends to 30 months. Q3 earnings call is scheduled for November 6, 2024.

The filing

CompanyCVS Health (CVS)
Form8-K, current report
Filed with the SECOct 18, 2024, 6:46 AM ET
Accession number0001193125-24-239193

Items reported: 2.02 Results of Operations5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 18, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.